Yang Y, Hoeflich A, Kessler U, Barenton B, Blum W, Schwarz H P, Kiess W
Children's Hospital, Department of Paediatric Endocrinology, University of Munich, Germany.
Regul Pept. 1993 Oct 20;48(1-2):41-53. doi: 10.1016/0167-0115(93)90334-5.
Human IM-9 lymphoblasts bind growth hormone (hGH) and insulin-like growth factors (IGFs). We have systematically examined the IM-9 cells as a valuable model of the interaction of hGH and the IGFs at the cellular level. Cells were cultured in medium with 10% serum and for a subset of experiments cultured in serum-free medium. Binding of [125I]hGH and [125I]IGF-I and -II to intact IM-9 cells was measured: unlabeled hGH inhibited binding of [125I]hGH (half max. 20 ng/ml). Binding of [125I]IGF-I was inhibited by IGF-I (half max. 7.5 ng/ml), IGF-II (half max. 60 ng/ml), and insulin and anti IGF-I receptor antibody (alpha IR3). [125I]IGF-II was inhibited by IGF-II (half max. 15 ng/ml), IGF-I (half max. 500 ng/ml), insulin (half max. 250 ng/ml) but not by alpha IR3. Crosslinking experiments with [125I]IGF-II and DSS as the crosslinking agent and analysis of radioligand-receptor complexes by SDS-PAGE under reducing conditions revealed that [125I]IGF-II bound to a 250 kDa and a 135 kDa receptor species. The latter possibly represents an insulin-type receptor whereas the 250 kDa species had the characteristics of the IGF-II/M6P receptor. When IM-9 cell conditioned medium was analyzed in ligand blotting experiments with either [125I]IGF-I or -II a 30 kDa IGFBP species was detected on the autoradiographs. Also, IGF-II immunoreactivity (approx. 1 ng/ml medium) was measured in the cell conditioned medium using an IGF-BP blocked RIA employing [125I]IGF-II. In a subset of experiments IM-9 cells were homogenized in 4 M guanidinium-thiocyanate and RNA extracted in 5.7 M CsCl. Denatured RNA was electrophoresed on 0.8% agarose gels and transferred to a nylon membrane, fixed and the blots hybridized with cDNA probes. Probes were labeled with [32P]dCTP using a random prime labeling procedure: a Pst I 700 bp fragment of the human IGF-I cDNA, a 554 bp Pst I-Sal I fragment of the IGF-II cDNA, a 614 bp Pst I fragment of the IGF-I receptor cDNA and a 663 bp Pst I fragment of the IGF-II/M6P receptor. Autoradiographs of Northern blots showed specific hybridization with the IGF-I probe at 3.7 kb and with the IGF-II probe at 5.3 kb. No signal was detected with the IGF-I receptor cDNA probe. Hybridization with the IGF-II/M6P receptor probe yielded a 9 kb RNA species.(ABSTRACT TRUNCATED AT 400 WORDS)
人IM-9淋巴母细胞可结合生长激素(hGH)和胰岛素样生长因子(IGF)。我们已系统地研究了IM-9细胞,将其作为hGH与IGF在细胞水平相互作用的一个有价值的模型。细胞在含10%血清的培养基中培养,部分实验在无血清培养基中进行。测定了[125I]hGH和[125I]IGF-I及-II与完整IM-9细胞的结合:未标记的hGH抑制[125I]hGH的结合(半数最大抑制浓度为20 ng/ml)。[125I]IGF-I的结合受到IGF-I(半数最大抑制浓度为7.5 ng/ml)、IGF-II(半数最大抑制浓度为60 ng/ml)、胰岛素和抗IGF-I受体抗体(αIR3)的抑制。[125I]IGF-II的结合受到IGF-II(半数最大抑制浓度为15 ng/ml)、IGF-I(半数最大抑制浓度为500 ng/ml)、胰岛素(半数最大抑制浓度为250 ng/ml)的抑制,但不受αIR3的抑制。以[125I]IGF-II和二硫代琥珀酰亚胺酯(DSS)作为交联剂进行交联实验,并在还原条件下通过SDS-PAGE分析放射性配体-受体复合物,结果显示[125I]IGF-II与一种250 kDa和一种135 kDa的受体种类结合。后者可能代表胰岛素型受体,而250 kDa的种类具有IGF-II/M6P受体的特征。当用[125I]IGF-I或-II进行配体印迹实验分析IM-9细胞条件培养基时,在放射自显影片上检测到一种30 kDa的IGF结合蛋白(IGFBP)种类。此外,使用采用[125I]IGF-II的IGF-BP封闭放射免疫分析(RIA)法,在细胞条件培养基中检测到IGF-II免疫反应性(约1 ng/ml培养基)。在部分实验中,将IM-9细胞在4 M异硫氰酸胍中匀浆,并用5.7 M CsCl提取RNA。将变性RNA在0.8%琼脂糖凝胶上电泳,转移至尼龙膜,固定后,用cDNA探针杂交印迹。探针用[32P]dCTP通过随机引物标记法进行标记:人IGF-I cDNA的一个700 bp Pst I片段、IGF-II cDNA的一个554 bp Pst I-Sal I片段、IGF-I受体cDNA的一个614 bp Pst I片段和IGF-II/M6P受体的一个663 bp Pst I片段。Northern印迹的放射自显影片显示与3.7 kb的IGF-I探针和5.3 kb的IGF-II探针有特异性杂交。用IGF-I受体cDNA探针未检测到信号。与IGF-II/M6P受体探针杂交产生一种9 kb的RNA种类。(摘要截短至400字)